The active vitamin D metabolite 1,25(OH)2D3 and other synthetic VDR agonists are differentiation agents that enforce an epithelial state in carcinoma cells largely through the induction of key epithelial proteins and the inhibition of EMT. Here, VDR is linked to carcinoma.